Objective To analyze the relationship between plasma proprotein convertase subtilisin/kexin 9 (PCSK9) level and cardiovascular disease (CVD) death in maintenance hemodialysis (MHD) patients. Methods A total of 84 MHD patients treated in Lianyungang First People's Hospital from Jan 2019 to Dec 2020 were recruited as the research subjects. A total of 84 healthy volunteers from health examinations in the same period were recruited as the healthy control group. The relationship between plasma PCSK9 level and clinical and laboratory indexes was analyzed by Spearson correlation. The risk factors for CVD death in MHD patients were analyzed by multivariate logistic regression. The predictive value of plasma PCSK9 level for CVD death in MHD patients was assessed by ROC curve. Results The plasma PCSK9 level was significantly higher in MHD group than in healthy control group (t=8.775, P＜0.001). In the MHD patients, plasma PCSK9 level was significantly lower in the survival patients than in the patients died of CVD (t=7.638, P＜0.001). Plasma PCSK9 level was negatively correlated with Kt/V, albumin and high-density lipoprotein cholesterol (r=-0.421, -0.402 and -0.387 respectively; P<0.001, <0.001 and=0.001 respectively), and was positively correlated with low-density lipoprotein cholesterol, total cholesterol, triglyceride and leukocyte count (r=0.355, 0.395, 0.324 and 0.399 respectively; P=0.006, <0.001, =0.011 and <0.001 respectively). High plasma PCSK9 level was the independent risk factors for CVD death in MHD patients (OR=2.054, 95% CI: 1.421～6.293, P=0.002). The AUC of plasma PCSK9 level for predicting CVD death in MHD patients was 0.822 (95% CI: 0.711～0.904) with the sensitivity of 79.26% and the specificity of 72.55% when the cut-off value was set at 255.65ng/mL Conclusion Plasma PCSK9 level increases significantly in MHD patients, especially in those died of CVD. Plasma PCSK9 level is an independent risk factor for CVD death in MHD patients, and also has the predictive value for CVD death in MHD patients.
QIAO Juan
,
ZHOU Yuan-Yuan
,
MIAO Han
. Elevated level of plasma proprotein convertase subtilisin/kexin 9 is a risk factor for cardiovascular disease death in maintenance hemodialysis patients[J]. Chinese Journal of Blood Purification, 2022
, 21(10)
: 729
-733
.
DOI: 10.3969/j.issn.1671-4091.2022.10.006
[1]Lamprea-Montealegre J A, Shlipak M G, Estrella M M. Chronic kidney disease detection, staging and treatment in cardiovascular disease prevention[J]. Heart, 2021, 107(16):1282-1288.
[2]Su X, Zheng DQ, Wang M P, et al. Low density lipoprotein cholesterol is associated with increased risk of cardiovascular disease in participants over 70 years old: A prospective cohort study[J]. Nutr Metab Cardiovasc Dis, 2022, 32(2):447-455.
[3]Wang DD, Yang XX, Chen YL, et al. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression[J]. J Biol Chem, 2020, 295(47):15870-15882.
[4]崔朝初, 卢娜, 冯超丽, 等. 前蛋白转化酶枯草杆菌蛋白酶9及其抑制剂在动脉粥样硬化中的作用研究进展[J]. 新乡医学院学报, 2021, 38(3):213-219.
[5]张辉, 周文平, 刘刚琼, 等. 前蛋白转化酶枯草杆菌蛋白酶9与稳定性冠心病患者冠状动脉病变严重程度的关系研究[J]. 临床心血管病杂志, 2019, 35(6):506-509.
[6]陆琦, 陈旭姣, 鲍迎春. 冠心病患者二肽基肽酶-4,前蛋白转化酶枯草杆菌蛋白酶-9,同型半胱氨酸水平与冠状动脉病变严重程度的相关性分析[J]. 心脑血管病防治, 2021, 21(6):539-542.
[7]Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation[J]. Proc Natl Acad Sci, 2003, 100(3): 928-933.
[8]Packard C, Chapman MJ, Sibartie M, et al. Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges[J]. Heart, 2021, 107(17):1369-1375.
[9]Kobayashi D, Mizuno A, Shimbo T, et al. The association of repeatedly measured low-density lipoprotein cholesterol and all-cause mortality and cardiovascular disease in dyslipidemic patients: A longitudinal study[J]. Int J Cardiol, 2020, 311(1):97-103.
[10]戴雨如, 杨阳, 柯亭羽. PCSK9抑制剂在降低心血管事件风险中的研究进展[J]. 中国医药科学, 2022, 12(1):39-42.
[11]崔佳, 丁秀丽, 赵培, 等. 抗磷脂综合征患者PCSK9基因突变与动脉粥样硬化的相关性[J]. 中华实用诊断与治疗杂志, 2021, 35(10):1043-1047.
[12]Haas ME, Levenson AE, Sun X, et al. The role of proprotein convertase subtilisin/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia clinical perspective[J]. Circulation, 2016, 134(1):61-72.
[13]刘莉, 叶鹏. 前蛋白转化酶枯草杆菌蛋白酶kexin-9在肾病综合征相关性高胆固醇血症中的作用[J]. 中华高血压杂志, 2016, 24(7):607.
[14]D'Ardes D, Santilli F, Guagnano MT, et al. From endothelium to lipids, through microRNAs and PCSK9: A fascinating travel across atherosclerosis[J]. High Blood Press Cardiovasc Prev, 2020, 27(1):1-8.
[15]Farahnak Z, Chapados N, Lavoie JM. Exercise training increased gene expression of LDL-R and PCSK9 in intestine: Link to transintestinal cholesterol excretion[J]. Gen Physiol Biophys, 2018, 37(3):309-317.
[16]Li S, Guo YL, Xu RX, et al. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease[J]. Atherosclerosis, 2014, 234(2):441-445.
[17]孟利民, 杨华, 信栓力, 等. 急性ST段抬高型心肌梗死患者早期应用PCSK9抑制剂对血清趋化素和白细胞介素37的影响[J]. 心脏杂志, 2022, 34(2):164-168.
[18]Basiak M, Buldak L, Konopka M, et al. Influence of PCSK9 inhibition on the stabilization of atherosclerotic plaque determined by biochemical methods and magnetic resonance imaging[J]. Atherosclerosis, 2018, 275(1):49-50.
[19]Kajingulu FPM, Lepira FB, Nkodila AN, et al. Circulating proprotein convertase subtilisin/kexin type 9 level independently predicts incident cardiovascular events and all-cause mortality in hemodialysis black Africans patients[J]. BMC Nephrol, 2022, 23(1):123-133.
